Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing

Clinical Pharmacology and Therapeutics · Published 2026-06-06 · DOI 10.1002/cpt.70356

Free full text

Authors (2)

Zakir Khan, Frank Moriarty

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Khan, Z., Moriarty, F. (2026). Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.70356

Related articles

• Reporting patterns of adverse drug withdrawal events using individual case safety reports in the FAERS and Eudravigilance databases · Exploratory Research in Clinical and Social Pharmacy · 2026 · Cites or is cited by this article
• Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• ASCPT News · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Reframing the Landscape for Achieving Equitable Pharmacotherapy Health Outcomes: Introducing Pharmacogenequity · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• The Multiple Criteria Qualitative Value‐Based Pricing Framework “ MARIE ” for Novel Cell and Gene Therapy · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• In This Issue · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• From Non‐Cancer Pain to Cancer Survivorship: Applying Opioid Deprescribing Lessons across the Divide · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation · Clinical Pharmacology and Therapeutics · 2026 · Same journal